NCT02253836已完成1 期
A Single-Centre Open-Label Study in Healthy Adult Volunteers to Assess the Pharmacokinetic Interactions Between Steady-State TPV (500 mg) and Single-Dose and Steady-State Atazanavir (300 mg QD) in the Presence of Ritonavir (100 mg)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
- 主要终点
- Maximum plasma concentration
研究概览
简要总结
Study to investigate the effects of steady-state TPV/r (500 mg/100 mg BID) on the single-dose and steady-state pharmacokinetics of Atazanavir (300 mg QD) co-administered with Ritonavir (100 mg). To investigate the effects of single-dose and steady-state Atazanavir (300 mg) on the steady-state pharmacokinetics of Tipranavir and Ritonavir.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects between 18 and 60 years of age inclusive
- •A Body Mass Index (BMI) between 18 and 29 kg/m2
- •Signed informed consent prior to trial participation
- •Ability to swallow multiple large capsules without difficulty
- •Acceptable laboratory values that indicate adequate baseline organ function at screening visit:
- •Laboratory values are considered to be acceptable if the severity of any parameter is ≤ Grade 1, based on the Division of AIDS/AIDS Clinical Trials Group Grading Scale
- •All abnormal laboratory values > Grade 1 are subject to approval by the trial clinical monitor
- •Acceptable medical history, physical examination, and 12-lead ECG at screening
- •Willingness to abstain from the following starting 2 weeks prior to administration of any study medication and up until the end of the study:
- •Grapefruit or grapefruit juice, Red wine, Seville oranges, St. John's Wort, and Milk Thistle
- •Willingness to abstain from alcohol starting 3 days prior to administration of any study medication up to the end of the study
- •Willingness to abstain from the following starting 3 days prior to pharmacokinetic (PK) sampling:
- •Garlic supplements and Methylxanthine containing foods or drinks (including coffee, tea, cola, energy drinks, chocolate, etc.)
- •Willingness to abstain from over-the-counter herbal medications for the duration of the study
- •Must be a non-smoker
- •Willingness to abstain from vigorous physical exercise during intensive PK Days 1, 9, 23, 24 and 32
- •Reasonable probability for completion of the study
排除标准
- •Female subjects of reproductive potential who:
- •Have positive serum pregnancy test
- •Have not been using a barrier method of contraception for at least 3 months prior to participation in the study
- •Are not willing to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and 60 days after completion/termination of the trial
- •Are breast-feeding
- •Participation in another trial with an investigational medicine within 2 months prior to Day 0 of this study
- •Use of any medication listed in the protocol within 30 days prior to Day 0 of this study
- •Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to Day 0 and for the duration of the study. Due to long half-life,subjects using of Depo-Provera within six months prior to Day 0 will be excluded from participation in this study
- •Use of hormone replacement therapy within 1 month prior to Day 0 and anytime during the study
- •Administration of antibiotics within 15 days prior to Day 0 and anytime during the study
- •History of acute illness within 60 days prior to Day 0
- •o Subjects will be excluded for acute illnesses that occurred more than 60 days prior to Day 0 if, in the opinion of the investigator, the subject does not qualify as a healthy volunteer
- •Have serological evidence of hepatitis B or C virus
- •Have serological evidence of exposure to HIV
- •Alcohol or substance abuse within 1 year prior to screening or during the study
- •Blood or plasma donations within 30 days prior to Day 0 or during the study
- •Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering Tipranavir, Ritonavir or Atazanavir to the subject
- •Subjects with pre-existing heart conduction abnormalities
- •Subjects who have taken (within 7 days prior to Day 0) any over-the-counter or prescription medication that, in the opinion of the investigator in consultation with the clinical monitor, might interfere with absorption, distribution, or metabolism of the study medications
- •Known hypersensitivity to sulphonamide class of drugs
- •Inability to adhere to the protocol
- •Cautions or warnings in the Ritonavir and Atazanavir package insert which, in the opinion of the investigator, constitute grounds for subject exclusion
研究组 & 干预措施
TAZ/RTV - TPV/RTV - TPV/RTV+TAZ
Experimental
Days 1-9: single dose TAZ/RTV
Days 16-23: morning and evening dose TPV/RTV
Days 24-32: TPV/RTV + TAZ
干预措施: Tipranavir (Drug)
TAZ/RTV - TPV/RTV - TPV/RTV+TAZ
Experimental
Days 1-9: single dose TAZ/RTV
Days 16-23: morning and evening dose TPV/RTV
Days 24-32: TPV/RTV + TAZ
干预措施: Ritonavir (Drug)
TAZ/RTV - TPV/RTV - TPV/RTV+TAZ
Experimental
Days 1-9: single dose TAZ/RTV
Days 16-23: morning and evening dose TPV/RTV
Days 24-32: TPV/RTV + TAZ
干预措施: Atazanavir (Drug)
结局指标
主要结局
Maximum plasma concentration
时间窗: up to day 33
Drug concentration in plasma at 12 hr after administration for Tipranavir (TPV) and Ritonavir (RTV)
时间窗: 12 hours after drug administration
Drug concentration in plasma at 24 hr after administration for Atazanavir (TAZ)
时间窗: 24 hours after drug administration
Area under plasma concentration time curve from 0-12 hours (AUC0-12h) for TPV and RTV
时间窗: up to 12 hours after drug administration
AUC0-24h for TAZ
时间窗: up to 24 hours after drug administration
次要结局
- Oral clearance(up to day 33)
- Elimination half-life(up to day 33)
- Time from dosing to the maximum concentration(up to day 33)
- Volume of distribution(up to day 33)
- Number of patients with adverse events(up to day 33)
研究者
相似试验
已完成
1 期
Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult VolunteersHealthyNCT02195466Boehringer Ingelheim20
已完成
1 期
Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of TipranavirHealthyNCT02251769Boehringer Ingelheim24
已完成
1 期
Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult VolunteersHealthyNCT02251171Boehringer Ingelheim24
已完成
1 期
VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.TelaprevirHIVHepatitis CNCT00775125Tibotec BVBA40
已完成
1 期
Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy SubjectsHealthyNCT04352361Ascletis Pharmaceuticals Co., Ltd.34